Jul 15, 2024 6:00am EDT Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
Jul 01, 2024 7:00am EDT Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
May 13, 2024 8:15am EDT Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
Apr 18, 2024 7:30am EDT Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Apr 18, 2024 7:00am EDT Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Apr 09, 2024 8:00am EDT Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
Feb 13, 2024 8:00am EST Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
Nov 30, 2023 7:00am EST Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Nov 17, 2023 8:00am EST Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference